首页> 外文OA文献 >ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas
【2h】

ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas

机译:ABCB1(MDR1)多态性与卵巢癌的进展和生存:卵巢癌协会联合会和癌症基因组图谱的综合分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance.We comprehensively evaluated this gene and flanking regions for an associationwith clinical outcome in epithelial ovarian cancer (EOC). Methods. The best candidates from fine-mapping analysis of 21 ABCB1 SNPs tagging C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642) were analysed in 4616 European invasive EOC patients from thirteen Ovarian Cancer Association Consortium(OCAC) studies and The Cancer Genome Atlas (TCGA). Additionally we analysed 1,562 imputed SNPs around ABCB1 in patients receiving cytoreductive surgery and either 'standard' first-line paclitaxel-carboplatin chemotherapy (n = 1158) or any first-line chemotherapy regimen (n = 2867). We also evaluated ABCB1 expression in primary tumours from 143 EOC patients. Result. Fine-mapping revealed that rs1128503, rs2032582, and rs1045642were the best candidates in optimally debulked patients. However, we observed no significant association between any SNP and either progression-free survivaloroverall survival inanalysis ofdata from14 studies. There was a marginal association between rs1128503 and overall survival in patients with nil residual disease (HR 0.88, 95% CI 0.77-1.01; p = 0.07). In contrast, ABCB1 expression in the primary tumour may confer worse prognosis in patients with sub-optimally debulked tumours. Conclusion. Our study represents the largest analysis of ABCB1 SNPs and EOC progression and survival to date, but has not identified additional signals, or validated reported associations with progression-free survival for rs1128503, rs2032582, and rs1045642. However, we cannot rule out the possibility of a subtle effect of rs1128503, or other SNPs linked to it, on overall survival. © 2013 The Authors. Published by Elsevier Inc. All rights reserved.
机译:目的。 ABCB1编码多药外排泵P-糖蛋白(P-gp),并与多药耐药有关。我们全面评估了该基因和两侧区域与上皮性卵巢癌(EOC)的临床结局的关系。方法。在来自13个卵巢癌协会联合会(OCAC)的13项卵巢癌侵袭性EOC患者中,对46种欧洲侵袭性EOC患者进行了21种标记为C1236T(rs1128503),G2677T / A(rs2032582)和C3435T(AscB2)的SBC精细映射分析的最佳候选者。癌症基因组图谱(TCGA)。此外,我们分析了接受减瘤手术和“标准”一线紫杉醇-卡铂化疗(n = 1158)或任何一线化疗方案(n = 2867)的患者中ABCB1附近的1562个估算SNP。我们还评估了143例EOC患者的原发性肿瘤中的ABCB1表达。结果。精细映射显示,rs1128503,rs2032582和rs1045642是最佳减员患者的最佳人选。然而,我们观察到任何SNP与无进展生存期或总体生存期分析14项研究数据之间均无显着关联。在零残留疾病患者中,rs1128503与总体生存率之间存在边际关联(HR 0.88,95%CI 0.77-1.01; p = 0.07)。相比之下,原发性肿瘤中ABCB1的表达可能会使肿瘤亚最佳的患者预后更差。结论。我们的研究代表了迄今为止对ABCB1 SNP和EOC进展及生存的最大分析,但尚未发现额外的信号,或未验证已报道的与rs1128503,rs2032582和rs1045642的无进展生存的关联。但是,我们不能排除rs1128503或与之相关的其他SNP对整体生存产生微妙影响的可能性。 ©2013作者。由Elsevier Inc.出版。保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号